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Abstract
b-defensin 2 is a small antimicrobial peptide of the innate immune system and has been thought to regulate anti-tumor
immunity. However, little is known on whether b-defensin 2 could modulate melanoma-specific NK and T cell responses. In
this study, we first cloned the murine b-defensin 2 gene by RT-PCR and generated the b-defensin 2 stably expressing B16
cells (B16-mBD2). Subsequently, we evaluated whether vaccination with irradiated B16-mBD2 could modulate the growth of
implanted B16 cells and determined the potential mechanisms underlying the action of B16-mBD2 vaccine in modulating
the growth of B16 tumors in C57BL/6. We found that vaccination with irradiated B16-mBD2, but not with control B16-p or
parental B16, inhibited the development and progression of B16 tumors, and prolonged the survival of tumor-bearing mice.
However, vaccination with irradiated B16-mBD2 failed to inhibit the development of B16 tumors in the CD4
+- or CD8
+-
depleted recipients. Furthermore, vaccination with irradiated B16-mBD2 stimulated strong NK activity and promoted potent
B16-specific CTL responses, accompanied by augmenting IFN-c and IL-12, but not IL-4, responses in the recipient mice.
Moreover, vaccination with irradiated B16-mBD2 promoted the infiltration of CD8
+ and CD4
+ T, NK cells and macrophages in
the tumor tissues. These data suggest b-defensin 2 may act as a positive regulator, promoting anti-tumor NK and T cell
responses in vivo. Therefore, b-defensin 2 may be used for the development of immunotherapy for the intervention of
melanoma.
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Introduction
Malignant melanoma is derived from melanocytes and its
incidence is currently increasing worldwide [1]. Although
melanoma is thought to be resistant to a wide range of systemic
chemotherapeutic agents, it is considered to be an immunogenic
tumor [2]. Hence, melanoma has become an excellent target for
anti-tumor immunotherapy. Many studies have attempted for the
development of vaccination, and previous studies have shown
promising efficacy of melanoma-based vaccines in inhibiting the
growth of melanoma cells in a number of murine melanoma
models [3,4]. However, the results of clinical trials are disappoint-
ed, and currently, there is no available vaccine with a clinically
proven efficacy against melanoma [2,5,6]. Design of new effective
vaccines for melanoma at clinic is currently one of the research
focuses in the anti-melanoma field. Theoretically, a vaccine for
inducing immune responses should depend on its immunogenicity.
Given the low immunogenicity of tumors, the efficacy of tumor-
based vaccines may depend not only on the type of vaccines, but
also on an ideal adjuvant for augmenting strong anti-tumor T cell
immunity [2]. However, currently available adjuvants used in
humans are unable to induce potent T cell immunity. Therefore,
the discovery of new adjuvants for the development of vaccines for
the immunotherapy of tumors will be of great significance.
Antimicrobial peptides are ancient arms of the innate immune
response in all life forms, and many of them can directly neutralize
invading microbes. Defensin is a family of small (3.5–4.5KD)
cationic antimicrobial peptides and widely distributed [7]. Recent
studies have demonstrated that defensins can modulate immune
responses [7,8]. Murine b-defensin 2 has chemo-attractant activity
for attracting immature dendritic cells, and can act as an
endogenous ligand for TLR4 to promote the maturation of
immature dendritic cells [9]. Given that dendritic cells are potent
antigen presenting cells their activation should promote T cell
immunity. Indeed, previous studies have shown that vaccination
with the plasmids encoding for low immunogenic lymphoma
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activated leukemia cells induces strong T cell immunity against
lymphoma and leukemia, respectively [10,11]. Furthermore, gene
therapy with plasmid encoding for the mFLK-1 antigen and b-
defensin 2 effectively inhibits the angiogenesis and growth of
tumor in vivo [12]. However, whether b-defensin 2 could modulate
melanoma antigen-induced NK and T cell responses has not been
explored.
In this study, we employed a mouse model of melanoma, and
tested the hypothesis that b-defensin 2 could act as an adjuvant to
augment potent anti-melanoma immunity and inhibit the
development and progression of melanoma in vivo. We first cloned
the mouse b-defensin 2 gene by RT-PCR from mouse kidney
tissue and generated stably b-defensin 2-expressing B16-mBD2
cells. Subsequently, we tested whether vaccination with sublethal-
irradiated B16-mBD2 cells could augment potent NK activity and
T cell immunity against melanoma in C57BL/6 mice. We found
that vaccination with irradiated B16-mBD2, but not with control
B16 or B16-p cells, inhibited the development and progression of
melanoma and prolonged the survival of tumor-bearing mice,
which was accompanied by inducing potent NK activity,
melanoma-specific CTL responses, and IFN-c and IL-12 produc-
tion as well as CD8
+ T, CD4
+ T, macrophage and NK cell
infiltration in the tumor tissues. Therefore, our data suggest that b-
defensin 2 can act as an adjuvant to augment anti-melanoma
immunity in vivo. We discussed the implications of our findings.
Materials and Methods
Cell lines
The C57BL/6-originated murine melanoma B16-F10 (desig-
nated as B16 here) cell line was a generous gift from Dr. Li-jing
Wang (Institute of Basic Medical Sciences, Guangdong Pharma-
ceutical University, Guangzhou, China). Although B16-F10 cells
were described as MHC-I negative [13], a low percentage of B16-
F10 cells maintained in our lab were positive for anti-Kb and anti-
Db staining (see below). Murine lymphoma Yac-1 cell line and
hepatic carcinoma Hepa 1–6 cell line were purchased from the
Cell Bank of Zhong-Shan Medical University, Guangzhou, China.
All cell lines were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 100 Units/mL of penicillin, and 100 mg/
mL of streptomycin at 37uC in a humidified 5% CO2 atmosphere.
Animals
Female C57BL/6 mice at 6–8 weeks of age were purchased
from the Center for Experimental Animals, Guangdong Province
(Guangzhou, China). The mice were housed at a specific pathogen
free facility of the Guangdong Provincial Key Laboratory of
Pharmaceutical Bioactive Substances. All studies involving mice
were approved by the Southern Medical University Animal Care
and Use Committee (permission No. 2009-089).
Plasmid construction
The murine b-defensin 2-expressing plasmid, pcDNA3.1(+)-Igk-
mBD2, was constructed. Briefly, total RNA was extracted from
C57BL/6 mouse kidney using Trizol (Invitrogen) and reversely
transcribed into cDNA using the SuperScriptH VILO
TM cDNA
Synthesis kit (Invitrogen), according to the manufacturer’s instruc-
tion. The gene for murine mature b-defensin 2 was amplified by
PCR using the cDNA as the template and the specific primers. The
sequences of primers were forward: 59-GAACTTGACCACTGC-
CACACC-39and reverse:59-GCTCTAGATTATCATTTCATG-
TACTTGCAAC-39. Subsequently, the DNA fragment was fused
with a sequence for murine Igk signal peptide by overlap-PCR
using the following primers corresponding to mouse Igk signal
peptide sequence (63 bp) and 21 bp of annealing to the mature b-
defensin 2 coding region. Recognition sequences of BamH I and Xba
I were added to the sense and antisense primers, respectively. The
sequences of all primers were sense 1: 59-CTGCTCTGGGTT-
CCAGGTTCCACTGGTGACGAACTTGACC ACTGCCA-
CACC-39; sense 2:59-CGGGATCCATGGAGTCAGACACAC-
TCCTGCTATGG GTACTGCTGCTCTGGGTTCCAGGTT-
CC-39; and antisense primer: 59-GCTCTAGATTA TCATTT-
CATGTACTTGCAAC-39. The PCR products were digested with
BamH I and Xba I, and then cloned into the same sites of
pcDNA3.1(+) vector, generating the plasmid of pcDNA3.1(+)-Igk-
mBD2. Its authenticity was demonstrated by DNA sequencing.
Transfection of B16 cells
B16 cells at 6610
5/well were cultured overnight in 10% FBS
RPMI 1640 (complete medium) in six-well plates and transfected
with 4.0 mg/well of pcDNA3.1(+)-Igk-mBD2 or control
pcDNA3.1(+), respectively, using Lipofectamine2000 reagent
(Invitrogen), according to the manufacturer’s instruction. After
being cultured for 24 h, the cells were treated with 0.5 mg/mL
G418 (Merck, Germany) in complete medium for 4 weeks.
Individual G418-resistant clones (B16-mBD2) were isolated and
screened for the expression of b-defensin 2. A similar procedure
was used for the generation of control B16-p clone that had been
transfected with control plasmid pcDNA3.1(+).
Expression of b-defensin 2
Individual transfectants at 10
6 cells/mL were cultured for 72 h,
and the cells and their supernatants were harvested. The levels of
b-defensin 2 mRNA transcripts and b-defensin 2 proteins secreted
in the supernatants were determined by RT-PCR and Western
blot assays, respectively. Briefly, total RNA was extracted from the
collected cells with Trizol, and reversely transcribed into cDNA.
The levels of b-defensin2 mRNA transcripts were determined by
PCR using the sense and anti-sense primers described above. The
supernatants were separated by SDS-PAGE using 16.5% Tris-
Tricine running gel and transferred electrically onto PVDF
membrane (Millipore, Bedford, USA). After being blocked with
5% non-fat milk in TBST [150 mmol/L NaCl, 10 mmol/L Tris,
and 0.05% Tween 20 (pH 8.0)] for 2 h at room temperature, the
membranes were incubated overnight with 1:400 diluted goat
polyclonal IgG antibodies against murine b-defensin 2 protein
(Santa Cruz, USA) in TBST at 4uC, and the bound antibodies
were detected with horseradish peroxidase (HRP)–conjugated
rabbit anti-goat IgG in TBST for 2 h at room temperature. The
immunocomplex was visualized by 3,39-diaminobenzidine (DAB).
In vivo immunization studies
C57BL/6 mice were vaccinated subcutaneously (s.c) in right
armpit with 1610
6 sublethal-irradiated B16-mBD2 cells, B16-p, or
parental B16 cells for the induction of B16-specific immunity,
respectively. One week after immunization, the mice were
inoculated s.c with 5610
4 parental B16 cells in left armpit. The
mice that had been injected with saline and inoculated with B16-p
or B16 cells were used as controls.
To evaluate the therapeutic effect of vaccination with B16-
mBD2 cells, C57BL/6 mice were inoculated s.c with 10
5 parental
B16 cells in left armpit, and the mice were injected in right armpit
with saline, or treated s.c with 10
6 sublethal-irradiated B16-mBD2
cells, B16-p cells, or parent B16 cells on day 0 and repeated three
times on day 3, 7, and 11, respectively. The tumor sizes was
measured with a caliper every other day up to 20 days post
inoculation in a blinded fashion, and the tumor volumes were
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3)=p/
66length (mm)6width (mm)6width (mm) [14]. The survival of
individual mice was recorded up to 150 days post inoculation.
To determine the role of CD4
+ T and CD8
+ T cells in the
vaccination-related therapy, CD4
+ and CD8
+ T cells were
depleted by treatment with the specific antibodies, respectively,
as described previously [15,16]. Briefly, groups of C57BL/6 mice
were treated intraperitoneally with 200 mg/mouse of anti-CD4
monoclonal antibody (GK1.5), anti-CD8a monoclonal antibody
(53–6.7) or rat IgG (eBioscience, San Diego, CA) daily on day 23,
22, 21, +6, +13, and +20, respectively. Three mice from each
group were sacrificed on day 0 and the efficacy of T cell depletion
was verified by flow cytometry analysis. Individual mice from those
groups were inoculated s.c with 10
5 B16 cells in left armpit and
vaccinated with irradiated B16-mBD2 in right armpit on day 0.
The mice were vaccinated with irradiated B16-mBD2 for three
more times on day 3, 7, and 11 as described above. Additional
groups of mice without antibody injection that had been
inoculated with B16 cells were vaccinated with B16-mBD2 or
injected with saline at each time point and used as positive or
negative controls for therapeutic studies, respectively. The tumor
sizes and the kinetics of tumor growth in vivo were measured and
analyzed as described above. The survival of individual mice was
monitored up to 120 days post inoculation.
CTL and NK cell assays
Splenic mononuclear cells were prepared from individual mice
one week after immunization. The cells were cultured at 37uC for
2 h and non-adherent cells were used as NK effector cells. To
prepare CTL effector cells, splenic mononuclear cells (5610
6)
were co-cultured with 5610
5 of mitomycin C (50 mg/mL, 40 min)
inactivated B16 cells in 5 mL RPMI 1640 containing 10% FBS
and 20 units/mL of recombinant IL-2 (Peprotech, Britain). Five
days later, the cells were harvested, purified by Ficoll gradient
centrifugation and used as CTL effector cells. The NK and CTL-
mediated cytotoxicities were determined by lactate dehydrogenase
(LDH) release assay. Briefly, Yac-1 cells at 2610
4/well were
cultured in quadruplicate with the prepared NK at the ratios of
12.5, 25, and 50 effector to target cells, respectively in 5% FBS
phenol-free RPMI 1640 in 96-well plates at 37uC for 4 h. The
target cells or effector NK cells cultured in medium alone
(negative) or treated with 1% triton X-100 (positive) were used as
controls, respectively. After centrifugation, their supernatants were
harvested and the contents of LDH were determined using the
CytoTox96 Non-Radioactive Cytotoxixity Assay kit, according to
the manufacturer’s instructions (Promega, Madison, USA). The
similar procedures were performed for CTL assays using B16 or
irrelevant syngeneic control hepa 1–6 cells as targets, respectively.
The cytotoxicity was calculated by the formula:
Lysis rate % ðÞ ~100|
experimental{effector spontaneous{target spontaneous ðÞ =
target maximum   target spontaneous ðÞ
Cytokine ELISA
Seven days post-immunization, splenic mononuclear cells were
isolated from individual mice, and the splenocytes (5610
6/well)
were challenged with mitomycin C (50 mg/mL, 40 min) inacti-
vated B16 cells (5610
5/well) in 10% FBS RPMI1640 in the
presence of 20 units/mL of IL-2 in 24-well plates for 48 h.
Subsequently, their supernatants were harvested and the contents
of IFN-c, IL-12, and IL-4 were determined by ELISA using mouse
IFN-c, IL-12, and IL-4 ELISA kits, according to the manufactur-
er’s instructions (R&D Systems, Minneapolis, USA).
Histological examination
On day 30 post-inoculation, subcutaneous tumor nodules were
dissected out from some mice of each group and fixed in 10%
Formalin solution, dehydrated, and embedded in paraffin. The
tumor tissue sections (5 mm) were stained with hematoxylin and
eosin (H&E), and examined under a light microscope.
Flow cytometry
On day 30 post-inoculation, subcutaneous tumor nodules were
dissected out from some mice of the B16-mBD2-vaccinated group
and the contents of CD4
+, CD8
+ T cells, NK cells, and
macrophages in the tumors were characterized by flow cytometry.
Briefly, the tumor tissues were minced small pieces and digested
with 0.05 g/L of collagenase IV (Roche, Indianapolis, IN) and
0.05% of DNase I (Roche) at 37uC for 45 min, followed by passing
through a stainless steel mesh (200 mM). After washing with D-
Hanks, mononuclear cells were separated by Ficoll density gradient
centrifugation. Subsequently, the cells were stained with anti-CD8-
FITC, anti-CD4-FITC, anti-CD3-PE, anti-NK1.1-PE,anti-CD3-
FITC, anti-F4/80-FITC and isotype control, respectively. The
frequency of CD4
+, CD8
+ T cells, NK cells and macrophages was
characterized by flow cytometry analysis on a FACScan using the
CellQuest software (Becton Dickinson, San Jose, USA).
Additional flow cytometry analysis was used for characterizing
the levels of H-2Kb/H-2Db on B16 cells using anti-H-2Kb-PE,
and anti-H-2Db-PE, respectively. Briefly, B16 cells were stimulat-
ed with, or without, 350 pg/mL of IFN-c for 4 or 24 h,
respectively, and the cells were stained with anti-H-2Kb-PE,
anti-H-2Db-PE and isotype controls, respectively, followed by flow
cytometry analysis.
Statistical analysis
Data are expressed as means 6 SD or representative
photoimages. The differences in individual measures among
different groups were analyzed by ANOVA and the survival
curves were plotted using Kaplan-Meier method and analyzed
using the standard Mantel-Cox log-rank test. Differences were
considered significant when a value of P,0.05.
Results
Cloning of the murine b-defensin 2 gene and
characterization of murine b-defensin 2 expression
To determine the role of b-defensin 2 in antitumor immunity,
the murine b-defensin 2 gene was amplified from the cDNA of
mouse kidney tissue by PCR. Subsequently, the DNA fragment
was fused with a sequence for Igk signal peptide and cloned into
plasmid pcDNA3.1(+), generating the plasmid pcDNA3.1(+)-Igk-
mBD2. After being sequenced, pcDNA3.1(+)-Igk-mBD2 and
control pcDNA3.1(+) were transfected into B16 cells, respectively.
Following G418 selection, the pcDNA3.1(+)-Igk-mBD2-transfect-
ed B16-mBD2 and control plasmid-transfected B16-p were
characterized for the expression of b-defensin 2 by RT-PCR,
respectively (Fig. 1A). Obviously, while there was no detectable b-
defensin 2 mRNA transcript in the parent B16 and the
pcDNA3.1(+)-transfected B16-p cells, a clear visible band was
detected in the B16-mBD2 cells. Hence, transfection of
pcDNA3.1(+)-Igk-mBD2 induced the transcription of b-defensin
2 mRNA in B16-mBD2 cells.
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B16-p, and parent B16 cells by Western blot assays revealed that the
b-defensin 2 protein was detected only in the B16-mBD2 cells, but
not in B16-p and parent B16 cells (Fig. 1B). Together, these data
indicated that the B16-mBD2 cells secreted b-defensin 2 in vitro.
Vaccination with irradiated B16-mBD2 cells inhibits the
growth of melanoma in vivo
b-defensin 2 is a immune regulator of innate and adaptive
immunity, and may promote antigen-specific T cell immunity
against malignant tumors [7]. To determine whether b-defensin 2
could enhance melanoma-specific T cell immunity, groups of
C57BL/6 mice were injected with saline or vaccinated with sub-
lethal irradiated B16-mBD2, B16-p, and patent B16 cells,
respectively. Seven days after vaccination, individual mice were
challenged s.c with 5610
4 of living parent B16 cells to establish
solid tumors, and the growth of melanoma was monitored
(Fig. 2A). The growth of solid melanoma in the mice vaccinated
with irradiated B16 or B16-p cells was indistinguishable from that
of the control mice received saline injection. In contrast, the
growth of melanoma in the mice that received B16-mBD2
vaccination was significantly slow. On day 20 post inoculation,
the mean tumor volume in the mice that had been vaccinated with
irradiated B16-mBD2 was about 16% of that in the mice injected
with saline or vaccinated with irradiated B16 cells. Furthermore,
all mice in the saline, B16-p, and parental B16 groups died within
49 days post inoculation, while more than 60% of the mice
vaccinated with B16-mBD2 survived. About 40% of the mice
remained alive independent of tumor at the end of the 150-day
observation period (P,0.01, by log-rank test, Fig. 2B). Apparently,
vaccination with irradiated B16-mBD2 cells prevented the
development of melanoma in mice.
Next, we examined whether vaccination with B16-mBD2 cells
could therapeutically inhibit the development of melanoma in vivo.
C57BL/6 mice were inoculated s.c with 10
5 of living parent B16
cells on day 0 and randomly injected with saline or treated with
10
6 of irradiated B16-mBD2, B16-p, and parent B16 cells on day
0, 3, 7, and 11, respectively. The development and progression of
melanoma were monitored (Fig. 2C). Clearly, treatment with
irradiated B16-mBD2 cells significantly inhibited the development
and progression of melanoma in mice. All of the mice that
received saline injection or irradiated B16-p, and parental B16
cells died within 44 days post-inoculation. In contrast, more than
80% of mice in the B16-mBD2 group remained alive on day 44
post inoculation, and nearly 30% of the mice remained alive free
of tumor at the end of 150-day observation period (P,0.01, by
log-rank test, Fig. 2D). Therefore, treatment with irradiated B16-
mBD2, but not B16-p and parental B16 cells, inhibited the
progression of melanoma and prolonged the survival of mice.
Vaccination with irradiated B16-mBD2 induces NK and
CTL responses and augments IL-12 and IFN-c production
To examine the mechanisms underlying the anti-melanoma
activity of irradiated B16-mBD2 vaccine, naive C57BL/6 mice
were vaccinated s.c. with 1610
6 irradiated B16-mBD2, B16-p, or
B16 cells, respectively. Seven days after vaccination, their splenic
mononuclear cells were isolated and cultured for 2 h, the
unadhered cells were used as NK effector cells. Additional splenic
mononuclear cells were stimulated with inactivated B16 cells in the
presence of IL-2 for 5 days, and lymphocytes were purified and
used as CTL effectors. The NK-mediated cytotoxicity against Yac-
1 cells and the CTL-mediated cytotoxicity against B16 cells or
control Hepa1–6 cells were determined by LDH assays. While low
levels of splenic NK cell activity were observed in the mice
vaccinated with B16-p or parental B16, the levels of splenic NK
activity against Yac-1 cells in the mice vaccinated with irradiated
B16-mBD2 increased by 2–4 folds (Fig. 3A). Similar patterns of
B16-specific splenic CTL responses were observed among these
groups of mice (Fig. 3B). However, there were similar weak CTL
responses to irrelevant syngeneic Hepa1–6 cells among these
groups of mice (Fig. 3C). Apparently, vaccination with irradiated
B16-mBD2, but not B16-p and parental B16, induced potent NK
and CTL responses in mice.
Activated NK and T cells as well as antigen presenting cells can
secrete pro-inflammatory cytokines, which promote and regulate
cellular immunity against tumors. Next, we analyzed B16-specific
IFN-c, IL-12, and IL-4 production in vitro. Splenic mononuclear
cells were isolated from individual groups of mice that had been
vaccinated with irradiated B16-mBD2, B16-p, parental B16, or
were injected with saline seven days after immunization and
stimulated with inactivated B16 cells in vitro for 48 h. The
concentrations of IFN-c, IL-12, and IL-4 in the harvested
supernatants were determined by ELISA (Fig. 3D). While similar
levels of IL-4 were detected among different groups of mice, the
levels of IFN-c and IL-12 in the supernatants of cultured splenic
mononuclear cells from the mice that received irradiated B16-
mBD2 cells were elevated by 4–7 folds, as compared with other
groups of mice. These data clearly indicated that vaccination of
Figure 1. The expression of b-defensin 2 in B16-mBD2 cells. B16 cells were transfected with the plasmid, pcDNA3.1(+)-Igk-b-defensin 2, or
control pcDNA3.1(+), respectively, and treated with G418 for the generation of b-defensin 2 stably-expressing cell clones. The expression of b-
defensin 2 was determined by RT-PCR and Western blot assays. (A) RT-PCR detection of b-defensin 2 mRNA. 1: The positive control plasmid
containing Igk-b-defensin 2 insert; 2: The pcDNA3.1(+)-Igk-b-defensin 2 transfected B16 cells; 3: The pcDNA3.1(+) transfected B16 cells; 4: The
parental B16 cells; M: DNA Marker. (B) Western-blot analysis of secreted b-defensin 2 peptides. M: protein Marker; 1: The supernatants of B16-mBD2; 2:
The supernatants of B16-p; 3: The supernatants of parental B16. Data shown are representative images from three separate experiments.
doi:10.1371/journal.pone.0031328.g001
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IFN-c and IL-12, but not IL-4.
Given that CTL responses depend on MHC-I expression and
vaccination with B16-mBD2 induced high levels (about 350 pg/
mL) of IFN-c production ex vivo, we examined whether IFN-c
secreted by activated T cells could enhance MHC-I expression on
B16. B16 cells were treated with, or without, 350 pg/mL of IFN-c
for 4 or 24 h and the levels of H-2Kb and H-2Db expression on
B16 cells were characterized by flow cytometry analysis. As shown
in Fig. 3E, we detected only 4.460.9% and 6.761.2% of H-2Kb
+
and H-2Db
+ B16 cells in the absence of IFN-c, and 43.265.8%
and 72.569.8% of H-2Kb
+ and H-2Db
+ B16 cells following
stimulation with IFN-c for 4 h, respectively (Fig. 3E, n=5). More
frequent of H-2Kb
+ and H-2Db
+ B16 cells were detected at 24 h
post stimulation (data not shown). These results demonstrated that
low frequency of B16 cells spontaneously expressed MHC-I and
IFN-c enhanced MHC-I expression on B16 cells.
Both CD4
+ and CD8
+ T are involved in the B16-mBD2
vaccine-induced antitumor immunity
To assess the role of CD4
+ or CD8
+ T cells in the B16-mBD2
vaccination-induced antitumor immunity, groups of C57BL/6 mice
were injected with control rat IgG, anti-CD4, or anti-CD8
monoclonal antibody to deplete CD4
+ or CD8
+ Tc e l l sa n dt h e
frequencies of splenic CD4
+ and CD8
+ T cells were characterized by
flow cytometry analysis three days after initial antibody treatment
(Fig. 4A). Clearly, the frequency of CD4
+ T cells in the anti-CD4-
treated mice and CD8
+ T cells in the anti-CD8-treated mice was
reduced by more than 90%, demonstrating the successful depletion
in these mice. Following inoculation of parent B16, vaccination with
irradiated B16-mBD2 cells, and continual treatment with antibody,
the growthofmelanoma(Fig.4B)and thesurvival ofdifferentgroups
of mice (Fig. 4C) were monitored. Tumor growth in the micetreated
with anti-CD8 was indistinguishable from that of the mice injected
Figure 2. Vaccination with irradiated B16-mBD2 inhibits the growth of implanted tumors and prolonged the survival of mice. (A, B)
The preventive effect of B16-mBD2 vaccination on the development of tumors. Groups of C57BL/6 mice were injected with saline or vaccinated with
irradiated parental B16 cells, B16-p cells, or B16-mBD2 cells, respectively, and the mice were inoculated s.c with B16 tumor cells one week later. The
growth of tumors in different groups of mice were monitored up to 20 days post inoculation (n=8 per group), and their survival was monitored up to
150 day post inoculation (n=8 per group). Data are a representative of three separate experiments and expressed as mean 6 SD of the tumor
volumes of each group of mice. (C, D) The therapeutic effect of vaccination with irradiated B16-mBD2 on the progression of implanted tumors.
Groups of C57BL/6 mice were inoculated s.c with B16 cells, and then injected with saline or treated with irradiated parental B16 cells, B16-p cells, or
B16-mBD2 cells for four times, respectively. The growth of tumors were monitored (n=8 per group), and their survival were monitored up to 150 day
post-treatment (n=8 per group). Data are a representative of three independent experiments and expressed as mean 6 SD of the tumor volumes of
each group of mice.
doi:10.1371/journal.pone.0031328.g002
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slightly slower than that of the mice treated with anti-CD8 and
injected withsaline.However,thetumorgrowthinthemicethat had
been vaccinated with B16-mBD2 and injected with rat IgG was
significantly slower than that ofthe otherthree groups. Furthermore,
we found that depletion of CD8
+ or CD4
+ T cells almost completely
abolished the therapeutic effects of the B16-mBD2 vaccine (Fig. 4C).
Evidentially, all of the mice that had been treated with anti-CD8,
inoculated with B16 cells and vaccinated with B16-mBD2 died
within 35 days post-inoculation, similar to that of saline-injected
mice. In contrast, more than 80% of the mice in the B16-mBD2
therapeutic group and rat IgG control group remained alive on day
35 post inoculation, which was significantly longer than the saline
treated control mice (P,0.01, by log-rank test). The mean survival
period of mice that had been injected with anti-CD4 was
significantly longer than that of the mice that had been injected
with anti-CD8(P,0.05,bylog-ranktest),but wasmuchshorterthan
that of the rat IgG-treated and B16-mBD2 treated mice (P,0.05, by
log-rank test, Fig. 4C). These data clearly indicated that both CD8
+
and CD4
+ T cells were the major players in the B16-mBD2-induced
antitumor immunity, particularly for CD8
+ T cells in this
experimental model.
Vaccination with irradiated B16-mBD2 promotes
mononuclear cell infiltration in tumor tissues
Finally, we examined whether B16-mBD2 vaccination could
modulate melanoma-related inflammation in the tumors. On 30
day post-inoculation, some mice from each group were sacrificed,
and their tumor nodules were dissected out for histological
examination. While there were a few mononuclear cells infiltrated
in the tumors from the mice that received saline injection or
vaccinated with B16 or B16-p cells, there were massive mononu-
clear infiltrates in the tumors from the mice vaccinated with B16-
mBD2 (Fig. 5A). Next, we isolated mononuclear cells from freshly
dissected tumors from the mice that had been vaccinated with
irradiated B16-mBD2 and characterized the frequency of CD4
+,
CD8
+ T cells, NK cells and macrophages by flow cytometry
analysis. We found that 25.569.6% of CD8
+ T, 21.766.2% of
CD4
+ T, 10.563.6% of NK cells and 15.265.8% of macrophages
in the tumors from the B16-mBD2-vaccinated mice (Fig. 5B). These
data suggested that vaccination with B16-mBD2 promoted the
Figure 3. Vaccination induces NK, CTL and cytokine responses. (A) NK activity. Groups of C57BL/6 mice were vaccinated with irradiated B16-
mBD2, B16-p, or B16, respectively, and one week later, their splenic mononuclear cells were isolated and used as NK effector cells. The NK effector
cells were mixed with Yac-1 cells at the indicated ratios for four hours, and the cytotoxicity of NK effectors against Yac-1 was determined by LDH
assays. (B, C) CTL response. Additional splenic mononuclear cells were challenged with inactivated B16 cells in vitro, and the lymphocytes were
purified and used as CTL effectors. The cytotoxicity of CTL effectors against B16 (B) or syngeneic irrelavant control Hepa1–6 (C) was determined by
LDH assays. Data are expressed as mean % 6 SD of each group of mice (n=3) from three independent experiments. (D) Cytokine responses. The
supernatants of cultured mixture of splenic mononuclear cells and inactivated B16 cells were harvested, and the concentrations of indicated
cytokines were determined by ELISA assays. Data are expressed as mean 6 SD of each group of mice (n=3) from three separate experiments. (E)
Spontaneous and inducible MHC-I expression in B16 cell. B16 cells were treated with, or without, 350 pg/mL of IFN-c for 4 or 24 h, respectively and
the levels of H-2K
b, H-2D
b expression on B16 cells were characterized by flow cytometry analysis. Data shown are representative histographes of each
group of cells from five separate experiments. Much more frequent of Kb
+ and Db
+ B16 cells were observed following treatment with IFN-c for 24 h
(data not shown).
doi:10.1371/journal.pone.0031328.g003
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+ T cells, NK cells and macrophages
in the tumors, an indicative of inflammation in the tumor tissues.
Discussion
Effective antitumor immunity should recognize tumor antigens
and destroy tumor cells in vivo [1]. However, many types of tumors
in humans have low immunogenicity and require an adjuvant to
induce an effective immune response. b-defensin 2 is an
antimicrobial peptide and can regulate immune response [8].
Previous studies have shown that vaccination with plasmids for the
fused protein of b-defensin 2 and tumor antigen or with b-defensin
2-expressing irradiated tumor cells stimulates strong antitumor
immune responses against lymphoma, leukemia, and mammary
adenocarcinoma in vivo [10,11,17,18]. In this study, we determined
whether b-defensin 2 could act as an adjuvant to induce
melanoma-specific T cell immunity in mice. First, we cloned the
gene for b-defensin 2 by RT-PCR and established the stable b-
defensin 2-expressing B16-mBD2 cell clone by transfecting the b-
defensin 2-expressing plasmid into B16 cells. Subsequently, we
characterized the expression of b-defensin 2 and found that the b-
defensin 2 mRNA transcripts were detected in B16-mBD2 cells, but
not in control B16-p cells that had been transfected with control
plasmid. Furthermore, we found that b-defensin 2 protein was
detected in the supernatants of cultured B16-mBD2, determined by
Western blot assays. These data suggested that b-defensin 2 was
secreted by B16-mBD2 cells in vitro. The successful establishment of b-
defensin 2-secreting B16-mBD2 cells provides a useful tool for further
investigating the effect of vaccination with the b-defensin 2-expressing
B16-mBD2 cells on the growth of implanted tumors in vivo.
Although sub-lethally irradiated tumor cells lack the ability to
proliferate, they can survive for a short period and may continually
secrete proteins. Indeed, we detected the expression of b-defensin
Figure 4. Pre-depletion of CD4
+ or CD8
+ T affects the therapeutic effect of B16-mBD2 vaccine in mice. (A) Flow cytometry analysis.
Groups of C57BL/6 mice were injected with rat IgG, anti-CD4 or anti-CD8 antibody, respectively and three day after the initial antibody treatment, the
frequency of splenic CD4
+ and CD8
+ T cells in some mice was characterized by flow cytometry analysis using FITC-anti-CD4, FITC-anti-CD8 and PE-
anti-CD3. Data shown are representative images of each group (n=3) of mice. (B, C) The effect of CD4
+ or CD8
+ depletion on the antitumor activity of
irradiated B16-mBD2 vaccine. The remaining mice were continually injected with the corresponding antibody, inoculated with parental B16 cells in
left armpit on day 0 and vaccinated with irradiated B16-mBD2 vaccine in right armpit on day 0, 3, 7, and 11. The growth of tumors was monitored
(n=3 per group), and their survival was monitored up to 120 days post inoculation (n=6 per group). Data are expressed as mean % of survival rates
of different groups of mice (n=6 per group).
doi:10.1371/journal.pone.0031328.g004
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irradiation, determined by RT-PCR (data not shown). Accord-
ingly, we irradiated the B16-mBD2, control B16-p, and parental
B16 cells, and tested whether vaccination with these cells could
prevent and inhibit the growth of implanted tumors in vivo. This
approach should vaccinate with majority of melanoma antigens
and produce b-defensin 2 in mice for a short period. We found
that pre-vaccination with irradiated B16-mBD2, but not with
control B16-p or parental B16 cells, effectively inhibited the
development of implanted melanoma in mice. More importantly,
vaccination with B16-mBD2 cells on the same day with the
implantation of melanoma cells also inhibited the development
and progression of melanoma tumors in mice. In addition,
vaccination with B16-mBD2 significantly prolonged the survival of
mice that had been inoculated with parental B16 cells. Moreover,
characterization of tumor tissues revealed many mononuclear cell
infiltrates, including CD8
+ and CD4
+ T cells, NK cells and
macrophages in the tumors from the mice that had been
vaccinated with B16-mBD2, indicating that vaccination with
B16-mBD2 induced a strong inflammation in the target tumors.
These data suggest that the B16-mBD2 melanoma vaccine may be
used for the therapeutic intervention of melanoma.
To understand the mechanisms underlying the protective effect
of B16-mBD2 vaccination on the growth of implanted melanoma,
we characterized the B16-mBD2-induced immune responses in
mice. We found that high NK activity and strong CTL responses
displayed in the mice vaccinated with B16-mBD2 cells, but not in
the mice vaccinated with control cells. The vaccine-induced CTL
responses appeared to be B16 melanoma-specific because similarly
low CTL responses to unrelated Hepa1–6 cells were present in
different groups of cells. Further analysis of the B16-stimualted
cytokines revealed that higher levels of IFN-c and significantly
elevated levels of IL-12, but not IL-4, were secreted by splenic
mononuclear cells from the mice vaccinated with B16-mBD2, but
not other groups of mice. Possibly, vaccination with irradiated
B16-mBD2 induced strong IFN-c responses, which further up-
regulated MHC-I expression on B16 cells, increasing their
sensitivity to CTL responses. Indeed, we found that low frequency
of B16 cells spontaneously expressed MHC-I and that the
frequency of B16 cells expressing MHC-I dramatically increased
following IFN-c stimulation in vitro. Notably, depletion of CD4
+ T
cells before vaccination significantly decreased the therapeutic
effect of B16-mBD2 vaccine while removing CD8
+ T cells almost
completely abrogated the B16-mBD2 vaccination-induced antitu-
mor effect, suggesting that both types of T cells were important,
but CD8+ T cells were the major mediators of the therapeutic
effect of B16-mBD2 vaccine. These data are consistent with the
notion that CD4
+ T cells provide help in priming antitumor CD8
+
CTL [19,20]. Interestingly, the tumor growth and survival period
of the CD4
+ T cell-depleted mice was slightly slower and
significantly longer than that of the CD8
+ T cell-depleted mice.
The slower tumor growth and the extended survival in the CD4
+
T cell-depleted mice may stem from the CD4-independent
activation of some CD8
+ T cells [21,22], which can inhibit the
growth of implanted tumor cells. Alternatively, a few CD4
+ T cells
in the anti-CD4-treated mice may be sufficient in providing help
for the activation of small population of CD8
+ T cells. Moreover,
characterization of tumor tissues revealed many mononuclear cells
infiltrated in the tumors from the mice vaccinated with B16-
mBD2, but not from other groups of tumors. Further character-
ization indicated that CD8
+ and CD4
+ T cells, NK cells, and
macrophages were predominant infiltrates in the tumors from the
B16-mBD2-vaccinated mice, indicating that vaccination with B16-
mBD2 induced a strong inflammation in the target tumors. IFN-c
is predominately secreted by activated Th1, CD8
+ T cells, and NK
cells while IL-12 is produced by activated antigen presenting cells.
Figure 5. Vaccination with B16-mBD2 promotes macrophage, NK and T cell infiltration into the melanoma tumors. (A) Histological
examination. On day 30 post inoculation, some tumor-bearing mice were sacrificed from each group and their tumors were dissected out, followed
by H&E staining. Data shown are representative images (6400) from the indicated group of mice (n=5). (B) Flow cytometry analysis of infiltrates. On
day 30 post inoculation, some tumor-bearing mice were sacrificed from the B16-mBD2-vaccinated mice and their tumor tissues were dissected out,
followed by digesting with collagenase and DNase I. Subsequently, mononuclear cells were isolated and stained with anti-F4/80-FITC, anti-CD4-FITC,
anti-CD8-FITC and anti-CD3-PE, or anti-NK1.1-PE and anti-CD3-FITC, respectively, followed by flow cytometry analysis. Data shown are representative
dot-plots or the mean % 6 SD of CD8
+CD3
+, CD4
+CD3
+, F4/80
+, NK1.1
+CD3
2 cells of five mice from three separate experiments.
doi:10.1371/journal.pone.0031328.g005
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tory Th1, CD8
+T cells, and activates NK cells, consistent with
previous findings [11,17]. As a result, the activated immunocom-
petent cells may migrate into the tumor tissues, inhibiting the
growth of implanted melanoma in mice. Hence, our study
provides additional evidence to support the notion that b-defensin
2 can act as an adjuvant to promote antitumor immunity in vivo.
Notably, Th17 cell responses have been thought to be crucial for
antitumor immunity. We are also interested in further investigat-
ing whether vaccination with B16-mBD2 could induce B16-
specific Th17 responses in mice.
b-defensin 2 has chemotactic activity and can recruit immature
dendritic cell migration through the receptor of CCR6 [7]. We
speculated that b-defensin 2 was produced by the irradiated B16-
mBD2 cells at least for couple days post-inoculation and it
recruited dendritic cells and other immunocompetent cells
through CCR6 into the vaccination site. Given that dendritic
cells have potent antigen presenting activity, they can capture and
present the apoptotic irradiated B16-mBD2 cell antigens to induce
strongly pro-inflammatory T cell immunity, which inhibits the
growth of implanted melanoma in mice. Apparently, b-defensin 2
acts as an adjuvant and provides a ‘‘danger signal’’ for stimulating
pro-inflammatory T cell responses. Indeed, b-defensin 2 has been
shown to promote the maturation of dendritic cells, which elicit
potent antitumor immunity against breast cancers in mice [18].
Therefore, b-defensin 2 may be used as an adjuvant to stimulate
pro-inflammatory T cell responses against tumors.
In summary, our data indicated that vaccination with the b-
defensin 2-expressing irradiated B16-mBD2 cells inhibited the
growth of implanted melanoma cells in mice. The therapeutic
effects of B16-mBD2 vaccination were likely mediated by vaccine-
induced strong pro-inflammatory NK and T cell immunity,
particularly for CD8
+ T cell responses, high levels of IFN-c and
IL-12 production and massive CD8
+ and CD4
+ T cell, NK and
macrophage infiltration in the tumor tissues. Our findings suggest
that b-defensin 2-expressing irradiated tumor cell-based vaccine is
a promising strategy for the induction of effective antitumor
immunity.
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